ClinicalTrials.gg
Not yet recruitingNCT07946211Updated Nov 18, 2026

Erector Spinae Plane Blocks for Pain Control After Total Laparoscopic Hysterectomy

An interventional study of Erector Spinae Plane Block and Deep Erector Spinae Plane Block in Postoperative Pain, sponsored by Hande Gurbuz. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Hande Gurbuz · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,104 studies in Pain, Postoperative with a site in Turkey — 267 open to participants now, 301 under way, none of them phase 3. Pain, Postoperative · Turkey.

Planned enrollment
256th of 889
87 · median 70
Started
2026
with 226 others
No phase
820 of 1,104
220 open now
Primary completion
2027-12
later than 289 of 300 live
Registered
1,102nd of 1,104
by date

Among the 1,104 studies in Pain, Postoperative with a site in Turkey, this one is the 256th largest by planned enrollment of the 889 interventional ones that give a count, is one of 227 that started in 2026, is one of 820 with no phase, reaches primary completion later than 289 of the 300 other live ones, and was the 1,102nd registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,238 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

267 of the 1,104 studies in Pain, Postoperative with a site in Turkey are open now. Recruiting first, the newest first:

262 more — sign in →

All 267 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,104 studies in Pain, Postoperative with a site in Turkey, or all of them as a file.
02

Study summary

This study will compare two nerve block techniques for pain relief after total laparoscopic hysterectomy, a minimally invasive operation to remove the uterus. Both techniques involve injecting a local anesthetic near muscles of the lower back, but the injections are given at different depths.

Women aged 18 to 65 years who are scheduled for this surgery will be randomly assigned to one of three groups: erector spinae plane block, deep erector spinae plane block, or no nerve block. The nerve blocks will be performed on both sides of the lower back after surgery. All participants will receive standard pain medication.

The main aim is to compare pain scores one hour after surgery. The study will also assess pain during the first 24 hours, opioid pain medication use, the time until additional pain relief is needed, nausea and vomiting, time to hospital discharge, patient satisfaction, and quality of recovery.

Read the detailed description

This single-center, prospective, randomized controlled study will compare ultrasound-guided bilateral erector spinae plane block and deep erector spinae plane block with a control group receiving no block in women undergoing total laparoscopic hysterectomy under general anesthesia.

Participants will be allocated to three groups using computer-generated randomization. Blocks will be performed postoperatively in the recovery unit at the L1 vertebral level. In the erector spinae plane block group, the injection will be administered between the erector spinae muscle and the transverse process. In the deep erector spinae plane block group, the injection will be administered deep to the transverse process, in the plane between the erector spinae and psoas muscles. Both block groups will receive 20 mL of 0.25% bupivacaine on each side. The control group will receive no block.

All groups will receive standardized general anesthesia and perioperative multimodal analgesia. Intravenous meperidine at 0.25 mg/kg will be administered as rescue analgesia when the numerical rating scale pain score exceeds 3.

An anesthesiologist blinded to group allocation will assess pain at rest and during movement. Baseline pain scores (0 minutes) will be recorded before block administration. Subsequent pain assessments in the block groups will be timed from completion of bilateral block administration. In the control group, an equivalent reference time will be established in the postoperative recovery unit, and the same assessment schedule will be followed. Postoperative assessments will include pain scores, opioid consumption, rescue analgesic requirements, nausea and vomiting, discharge time, patient satisfaction, and quality of recovery using the Quality of Recovery-15 questionnaire.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Total Laparoscopic Hysterectomy
  • Erector Spinae Plane Block
  • Deep Erector Spinae Plane Block
  • Postoperative Analgesia
  • Ultrasound-Guided Regional Anesthesia
  • Opioid Consumption
  • Quality of Recovery
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 65 years.
  • Scheduled for elective total laparoscopic hysterectomy.
  • (ASA) physical status I, II, or III.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • IV or higher.
  • Inability to cooperate with pain assessment because of cognitive impairment, a psychiatric condition, or inability to understand Turkish.
  • Known allergy to local anesthetics or opioids.
  • greater than 35 kg/m².
  • Infection at the planned injection site.
  • Neurological deficits.
  • Alcohol or drug dependence.
  • Known or suspected coagulopathy.
  • Severe hepatic, cardiac, or renal disease.
  • Emergency surgery or repeat surgery.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
87 participants (estimated)

Study arms

  • Active comparator
    Erector Spinae Plane Block

    Participants will receive an ultrasound-guided bilateral erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae muscle and the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed.

    Procedure: Erector Spinae Plane Block

  • Experimental
    Deep Erector Spinae Plane Block

    Participants will receive an ultrasound-guided bilateral deep erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed.

    Procedure: Deep Erector Spinae Plane Block

  • No intervention
    Control Group

    Participants will receive no nerve block. They will receive the same standardized perioperative multimodal analgesia as the two block groups, with rescue analgesia administered as needed.

Interventions

  • ProcedureErector Spinae Plane Block

    Ultrasound-guided bilateral erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected between the erector spinae muscle and the transverse process on each side.

  • ProcedureDeep Erector Spinae Plane Block

    Ultrasound-guided bilateral deep erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process, on each side.

06

What researchers measure

Primary outcomes

  1. Pain Intensity at Rest at 1 Hour After Block Administration

    Pain intensity at rest will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. Assessment will occur 1 hour after completion of bilateral block administration or the equivalent reference time in the control group.

    Time frame: At 1 hour after block administration or the equivalent reference time in the control group

Secondary outcomes

  1. Pain Intensity During Movement at 1 Hour After Block Administration

    Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. At 1 hour after block administration or the equivalent reference time in the control group

    Time frame: At 1 hour after Block Administration

  2. Pain Intensity at Rest Before and After Block Administration

    Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point.

    Time frame: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery

  3. Pain Intensity During Movement Before and After Block Administration

    Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point.

    Time frame: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery

  4. Cumulative Rescue Opioid Consumption During the First 24 Hours After Surgery

    The total dose of intravenous meperidine administered as rescue analgesia during the first 24 hours after surgery will be recorded in milligrams. Rescue analgesia will be administered at a dose of 0.25 mg/kg when the numerical rating scale (NRS) pain score exceeds 3. Higher consumption indicates a greater requirement for rescue opioid analgesia.

    Time frame: During the first 24 hours after surgery

  5. Time to First Rescue Analgesia

    The time from the end of surgery to the first administration of rescue analgesia will be recorded in minutes. Intravenous meperidine at 0.25 mg/kg will be administered when the numerical rating scale (NRS) pain score exceeds 3. Participants who do not receive rescue analgesia during the first 24 hours will be censored at 24 hours.

    Time frame: From the end of surgery to the first administration of rescue analgesia, up to 24 hours

  6. Postoperative Nausea and Vomiting Severity

    Postoperative nausea and vomiting will be assessed using a five-point scale: 0 = none, 1 = mild nausea, 2 = moderate nausea, 3 = one episode of vomiting, and 4 = more than one episode of vomiting. Higher scores indicate greater severity.

    Time frame: During the first 24 hours after surgery

  7. Quality of Recovery at 24 Hours After Surgery

    Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The questionnaire contains 15 items, with a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The questionnaire will be administered preoperatively and at 24 hours after surgery.

    Time frame: Preoperatively and at 24 hours after surgery

07

Study locations

1 site
  • University of Health Sciences, Bursa City Hospital
    Bursa, Bursa 16110, Turkey (Türkiye)
08

References and documents

Publications

  • Baran O. Quadratus lumborum and erector spinae plane blocks are effective for analgesia in laparoscopic hysterectomy: a randomized controlled trial. Eur Rev Med Pharmacol Sci. 2023 Dec;27(23):11323-11333. doi: 10.26355/eurrev_202312_34571. PubMed 38095381 ↗
  • Kilicaslan A, Ciftci B, Aycan IO, Arici AG, Kilic G, Cakin H, Yilmaz R, Alver S, Temel H, Sindel M. Lumbar erector spinae plane block: which side of the fascia? The role of injection depth and volume in a cadaveric model. Pain Med. 2026 May 1;27(5):610-612. doi: 10.1093/pm/pnaf171. No abstract available. PubMed 41344320 ↗

Individual participant data

Plan to share: No — There is currently no plan to share individual participant data with other researchers.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 2,101 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 13 months is above that.

Counting every sponsor, half of 2,114 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946211
Lead sponsor
Hande Gurbuz
Responsible party
Hande Gurbuz (Prof, MD, PhD, Bursa City Hospital) — Sponsor-investigator
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Hande Gurbuz, Prof, MD, PhD
Contact
handegrbz@gmail.com
+90 533 651 56 50
Hande Gurbuz, Prof, MD, PhD
principal investigator · University of Health Sciences, Bursa School of Medicine, Bursa City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion